In vivo biochemical indices of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer 344 rat
- PMID: 3350230
- DOI: 10.1016/0272-0590(88)90251-5
In vivo biochemical indices of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer 344 rat
Abstract
In vivo biochemical indices of nephrotoxicity were investigated in Fischer 344 rats treated with a new platinum analog, tetraplatin [tetrachloro(dl-trans)1,2-diaminocyclohexane platinum(IV), NSC-363812], in comparison with rats receiving equimolar dosages of cisplatin and CHIP [cis-dichloro,trans-dihydroxybis-isopropylamine platinum(IV), NSC-256927]. The goals of this study were to assess the comparative nephrotoxicities and to determine which battery of tests might be useful for the assessment of platinum analog-induced nephrotoxicity in future clinical investigations of these drugs. An iv bolus injection of 6.7, 13.3, 26.7, and 53.3 mumol/kg of each drug in saline was administered and assessment of biochemical parameters was conducted for 15 days postinjection. A combination of urinary enzyme and protein excretion rates along with blood urea nitrogen (BUN) determinations was used to assess the nephrotoxicity of these compounds. At equimolar dosages, tetraplatin appeared to be less nephrotoxic than cisplatin, and CHIP was not nephrotoxic. At all dosages tested, cisplatin increased the rate of urinary excretion of protein, lactate dehydrogenase (LDH), and N-acetylglucosaminidase (NAG) between Days 1 and 5. Tetraplatin did not affect these parameters until the 13.3 mumol/kg dosage. Cisplatin had little effect on the excretion rates of the brush border enzymes alkaline phosphatase and maltase, whereas tetraplatin caused an initial elevation with delayed onset of peak excretion rates at 8 days postinjection. Changes in BUN were not evident until after the 13.3 mumol/kg dosage of cisplatin and the 26.7 mumol/kg dosage of tetraplatin. BUN was useful for ranking the relative toxicities of the three compounds tested, but was not as sensitive in detecting the onset of injury that correlated with early histopathological changes. Tetraplatin appeared to be less nephrotoxic than cisplatin on an equimolar basis and the specific manifestations of its toxicity were different from those observed with cisplatin. Urinary excretion rates for LDH, NAG, and protein proved to be sensitive indicators of platinum analog-induced nephrotoxicity. These indices, combined with BUN determinations and functional assessments, facilitated comparisons of the nephrotoxicity induced by cisplatin and tetraplatin in rats.
Similar articles
-
Comparative toxicity and renal distribution of the platinum analogs tetraplatin, CHIP, and cisplatin at equimolar doses in the Fischer 344 rat.Fundam Appl Toxicol. 1988 Jan;10(1):45-61. doi: 10.1016/0272-0590(88)90250-3. Fundam Appl Toxicol. 1988. PMID: 3350229
-
Reduction of tetrachloro(dl-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) toxicity by the administration of diethyldithiocarbamate (DDTC), S-2(3-aminopropylamino)ethylphosphorothioic acid (WR-2721), or sodium selenite in the Fischer 344 rat.Fundam Appl Toxicol. 1990 May;14(4):706-19. doi: 10.1016/0272-0590(90)90296-v. Fundam Appl Toxicol. 1990. PMID: 2163338
-
Comparative nephrotoxicity of tetraplatin and cisplatin in rats.Nephron. 1993;64(2):289-95. doi: 10.1159/000187328. Nephron. 1993. PMID: 8321364
-
Cisplatin nephrotoxicity: a summary of preventative interventions.Drug Intell Clin Pharm. 1985 May;19(5):362-7. doi: 10.1177/106002808501900505. Drug Intell Clin Pharm. 1985. PMID: 3891281 Review.
-
Platinum-based chemotherapies-induced nephrotoxicity: mechanisms, potential treatments, and management.Int Urol Nephrol. 2025 May;57(5):1563-1583. doi: 10.1007/s11255-024-04303-2. Epub 2024 Dec 4. Int Urol Nephrol. 2025. PMID: 39630371 Review.
Cited by
-
Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812).Invest New Drugs. 1999;17(1):63-72. doi: 10.1023/a:1006223100561. Invest New Drugs. 1999. PMID: 10555124 Clinical Trial.
-
Organ-specific biotransformation of ormaplatin in the Fischer 344 rat.Cancer Chemother Pharmacol. 1995;36(5):439-47. doi: 10.1007/BF00686194. Cancer Chemother Pharmacol. 1995. PMID: 7634386
-
Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.Cancer Chemother Pharmacol. 1995;36(5):431-8. doi: 10.1007/BF00686193. Cancer Chemother Pharmacol. 1995. PMID: 7634385
-
Blood gene expression markers to detect and distinguish target organ toxicity.Mol Cell Biochem. 2010 Feb;335(1-2):223-34. doi: 10.1007/s11010-009-0272-5. Epub 2009 Sep 26. Mol Cell Biochem. 2010. PMID: 19784758
-
The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).Jpn J Cancer Res. 1993 Jan;84(1):83-92. doi: 10.1111/j.1349-7006.1993.tb02788.x. Jpn J Cancer Res. 1993. PMID: 8383649 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical